Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
ANNÉE
2018
AUTEURS
Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS
CONGRÈS/REVUE
BMC Cancer
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES